mbiomics Announces Third Closing of Series A, Reaching €30 Million to Advance Microbiome Therapeutics
mbiomics GmbH, a pioneering techbio company advancing scalable microbiome-based therapeutics for severe and chronic diseases, today announced the successful third closing of its Series A round at €12 million, bringing the total round size to […]
